{"id":"NCT02294227","sponsor":"Novartis Pharmaceuticals","briefTitle":"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-29","primaryCompletion":"2016-02-16","completion":"2017-12-19","firstPosted":"2014-11-19","resultsPosted":"2019-07-02","lastUpdate":"2019-07-02"},"enrollment":341,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Psoriatic"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab 150 mg","type":"EXPERIMENTAL"},{"label":"Secukinumab 150 mg No load","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active PsA despite current or previous NSAID or DMARD therapy","primaryOutcome":{"measure":"Number of Participants With American College of Rheumatology 20 (ACR20) Response","timeFrame":"16 weeks","effectByArm":[{"arm":"Secukinumab 150 mg","deltaMin":47,"sd":null},{"arm":"Secukinumab 150 mg No Load","deltaMin":45,"sd":null},{"arm":"Placebo","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.0002"},{"comp":"OG000 vs OG002","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":64,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","France","Germany","Italy","Poland","Russia","Sweden","United Kingdom"]},"refs":{"pmids":["38446397","34795065","31228101"],"seeAlso":["http://www.novartisclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":334},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Sinusitis","Headache"]}}